Razelle Kurzrock, Founding Director of Michels Rare Cancers Research Laboratories at the Medical College of Wisconsin and Co-Founder and Board Member at CureMatch, shared a post on X:
“We seem to be debating whether it’s worthwhile to do a cheap HER2 IHC if HER2 is rare. Biopsies have an average of 5-12 IHCs done routinely. No one questions that.
If you miss the HER2 diagnosis, the patient can be treated with ineffective therapy, which presumably saves money.”
More posts featuring Razelle Kurzrock.